Investor Presentaiton

Key Deals & Rationale SUN PHARMA Year Deals Country 2015 Acquired InSite Vision Inc. US 2015 Acquisition of GSK's Opiates Business Global Markets 2015 Distribution agreement with AstraZeneca India 2015 Sun Pharma - Ranbaxy Merger Global Markets 2014 In-licensing agreement with Merck for MK-3222 a biologic for psoriasis Global Markets 2014 Acquired Pharmalucence US 2013 Formation of Sun-Intrexon JV Global Markets 2013 Acquired URL's generic business US 2012 Acquired DUSA Pharma, Inc. US Rationale Strengthens branded ophthalmic portfolio in U.S. Vertical Integration for controlled substances business Distribution services agreement in India for brand "Axcer"Ⓡ (brand of ticagrelor, used for the treatment of acute coronary syndrome) 5th largest Global Specialty Generic Pharma Company, No.1 Pharma Company in India & Strong positioning in Emerging Markets Strengthening the specialty product pipeline Sterile injectable capacity in the US, supported by strong R&D capabilities JV for ocular therapies Adds 107 products to US portfolio Access to branded derma product 2011 Formation of Sun-MSD JV Emerging Markets Develop and commercialize technology based combinations products Acquired Taro Pharmaceutical 2010 Israel Industries Ltd. 2008 Acquired Chattem Chemicals, Inc. Tennessee, US Assets of Able Labs 2005 Formulation plant in Bryan New Jersey, US Ohio, US Dermatology & Topical Product Manufacturing Plant at Israel & Canada Import registration with DEA, API Plant approved by DEA in Tennessee, US Dosage form plant (NJ, US) and IP Dosage form plant (Ohio, US) 1997 Acquired Caraco Detroit, US Entry into US Market Sun Pharmaceutical Industries Limited. All Rights Reserved. 14

View entire presentation